These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19639315)

  • 1. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
    Addeo R; De Santi MS; Del Prete S; Caraglia M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
    Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
    Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
    Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
    BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
    De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
    Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
    Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
    J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL
    Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
    [No Abstract]   [Full Text] [Related]  

  • 7. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
    Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
    J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
    Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
    Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lecture: fotemustine in brain tumors.
    Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
    Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
    Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
    J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on Fotemustine.
    De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
    J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
    Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of brain tumors: biological basis of its limited efficacy].
    Mousseau M
    Bull Cancer; 1994 May; 81(5):414-24. PubMed ID: 7749219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
    Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
    Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
    Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A
    J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
    Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S
    J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
    Lombardi G; Della Puppa A; Zustovich F; Pambuku A; Farina P; Fiduccia P; Roma A; Zagonel V
    Biomed Res Int; 2014; 2014():678191. PubMed ID: 24812626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of chemotherapy for malignant brain tumors].
    Takeshima H; Kuratsu J
    No Shinkei Geka; 2003 Jul; 31(7):725-34. PubMed ID: 12884787
    [No Abstract]   [Full Text] [Related]  

  • 20. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
    Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
    Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.